Chronic spontaneous urticaria or urticarial vasculitis?

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic spontaneous urticaria is the spontaneous appearance of blisters, angioedema, or both for >6 weeks that affects up to 0.5%–5% of the population, mainly females. Spontaneous wheals and/or angioedema, severe skin itching that leads to depression and anxiety, sleep disturbances, sexual dysfunction, and activity of daily life and work restrictions. Other diseases sometimes occur under the guise of chronic spontaneous urticaria.

Urticarial vasculitis is a vasculitis of the small skin vessels, characterized by the duration of persistent skin rashes in combination with histopathological features of leukocytoclastic vasculitis. Differential diagnosis of chronic spontaneous urticaria and urticarial vasculitis is conducted in the case of an atypical clinical picture of urticaria. Wheals lasted for >24 h, often accompanied by burning and pain, and leaving behind purpura or residual hyperpigmentation.

Herein, described a case of urticarial vasculitis in a patient that required a differential diagnosis of chronic spontaneous urticaria and urticarial vasculitis several years after the disease onset. Successful treatment was conducted with a combination of antihistamines, glucocorticosteroids, hydroxychloroquine, and omalizumab.

Full Text

Restricted Access

About the authors

Irina V. Dorofeeva

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: idorofeeva1@gmail.com
ORCID iD: 0000-0002-4423-1797
SPIN-code: 5480-4193
Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522

Inna V. Danilycheva

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: ivdanilycheva@mail.ru
ORCID iD: 0000-0002-8279-2173
SPIN-code: 4547-3948

MD, Cand. Sci. (Med.)

Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522

Andrey E. Shuljenko

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Author for correspondence.
Email: shulzhenko_ae@mail.ru
ORCID iD: 0000-0003-0268-9350
SPIN-code: 4584-4915

MD, Dr. Sci. (Med.), Professor

Russian Federation, 24, Kashirskoyw shosse, Moscow, 115522

References

  1. Zuberbier T, Aberer W, Asero R, et al. The EAACI/ GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. doi: 10.1111/all.13397
  2. Federal Clinical guidelines for the diagnosis and treatment of urticaria. Russian Association of Allergists and Clinical Immunologists; 2019. (In Russ).
  3. Guillén-Aguinaga S, Jáuregui Presa I, Aguinaga-Ontoso E, et al. Updosing nonsedating antihistamines in patients with chronic spontaneous urticaria: a systematic review and meta-analysis. Br J Dermatol. 2016;175(6):1153–1165. doi: 10.1111/bjd.14768
  4. Maurer M, Staubach P, Raap U, et al. ATTENTUS, a German online survey of patients with chronic urticaria highlighting the burden of disease, unmet needs and real-life clinical practice. Br J Dermatol. 2016;174(4):892–894. doi: 10.1111/bjd.14203
  5. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66(3):317–330. doi: 10.1111/j.1398-9995.2010.02496.x
  6. Eun S, Lee J, Kim D, Yoon H. Natural course of new-onset urticaria: results of a 10-year follow-up, nationwide, population-based study. Allergol Int. 2019;68(1):52–58. doi: 10.1016/j.alit.2018.05.011
  7. O’Donnell B, Lawlor F, Simpson J, et al. The impact of chronic urticaria on the quality of life. Br J Dermatol. 1997;136(2):197–201.
  8. Kozel M, Mekkes J, Bossuyt P, Bos J. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45(3):387–391. doi: 10.1067/mjd.2001.116217
  9. Van der Valk P, Moret G, Kiemeney L. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol. 2002;146(1):110–113. doi: 10.1046/j.1365-2133.2002.04582.x
  10. Thomsen SF, Pritzier EC, Anderson CD, et al. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the noninterventional multicentre AWARE study. JEADV. 2017;31(6):1048–1055. doi: 10.1111/jdv.14210
  11. Costa C, Rosmaninho I, Guilherme A, et al. Chronic urticaria in the real-life clinical practice setting in Portugal: baseline results from the non-interventional multicentre AWARE study. Acta Med Port. 2019;32(2):133–140. doi: 10.20344/amp.9496
  12. Konstantinou GN, Konstantinou GN. Psychiatric comorbidity in chronic urticaria patients: a systematic review and meta-analysis. Clin Transl Allergy. 2019;9:42. doi: 10.1186/s13601-019-0278-3
  13. Tat T. Higher Levels of depression and anxiety in patients with chronic urticaria. Med Sci Monit. 2019;25:115–120. doi: 10.12659/MSM.912362
  14. Gonçalo M, Arnau GA, Al‐Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatology. 2021;184(2):226–236. doi: 10.1111/bjd.19561
  15. Caproni M, Verdelli A. An update on the nomenclature for cutaneous vasculitis. Curr Opin Rheumatol. 2019;31(1):46–52. doi: 10.1097/BOR.0000000000000563
  16. Kolkhir P, Grakhova M, Bonnekoh H, et al. Treatment of urticarial vasculitis: a systematic review. J Allergy Clin Immunol. 2019;143(2):458–466. doi: 10.1016/j.jaci.2018.09.007
  17. Kolkhir P, Bonnekoha H, Kocatürkc E, et al. Management of urticarial vasculitis: a worldwide physician perspective. World Allergy Organ J. 2020;13(3):100107. doi: 10.1016/j.waojou.2020.100107
  18. Dincy CV, George R, Jacob M, et al. Clinicopathologic profile of normocomplementemic and hypocomplementemic urticarial vasculitis: a study from South India. J Eur Acad Dermatol Venereol. 2008;22(7):789–794. doi: 10.1111/j.1468-3083.2007.02641.x
  19. O’Donnell B, Black AK. Urticarial vasculitis. Int Angiol. 1995;14(2):166–174.
  20. Cardoso PA, de Oliveira ZP, Alves VA, et al. Urticarial vasculitis. Allergol Immunopathol. 1990;18(4):191–195.
  21. Peteiro C, Toribio J. Incidence of leukocytoclastic vasculitis in chronic idiopathic urticaria. Study of 100 cases. Am J Dermatopathol. 1989;11(6):528–533. doi: 10.1097/00000372-198912000-00003
  22. Borzova E., Grattan С.E. Urticarial Vasculitis. In: Griffiths C.E., Barker J., Bleiker T.O., et al. Rook’s textbook of dermatology. Vol. 4 Set, 9th Edition. UK, Wiley Blackwell; 2016. Р. 44.1.
  23. Wisnieski JJ. Urticarial vasculitis. Curr Opin Rheumatol. 2000;12(1):24–31. doi: 10.1097/00002281-200001000-00005
  24. Mehregan DR, Gibson LE. Pathophysiology of urticarial vasculitis. Arch Dermatol. 1998;134(1):88-89. doi: 10.1001/archderm.134.1.88
  25. Kano Y, Orihara M, Shiohara T. Cellular and molecular dynamics in exercise‐induced urticarial vasculitis lesions. Arch Dermatol. 1998;134(1):62–67. doi: 10.1001/archderm.134.1.62
  26. Gammon WR. Urticarial vasculitis. Dermatol Clin. 1985;3(1):97–105.
  27. Danilycheva IV. Urticarian vasculitis: diagnostic algorithm. Doktor.Ru. 2009;2(46):67–72. (In Russ).
  28. Kolkhir PV. Urticar vasculitis. Urticaria and angioedema. Moscow: Practical Medicine; 2012. Р. 286–297. (In Russ).
  29. Venzor J, Lee WL, Huston DP. Urticarial vasculitis. Clin Rev Alleergy Immunol. 2002;23(2):201–211. doi: 10.1385/CRIAI:23:2:201
  30. Dincy CV, George R, Jacob M, et al. Clinicopathologic profile of normocomplementemic and hypocomplementemic urticarial vasculitis: a study from South India. J Eur Acad Dermatol Venereol. 2008;22(7):789–794. doi: 10.1111/j.1468-3083.2007.02641.x
  31. Davis MD, Daoud MS, Kirby B, et al. Clinicopathologic correlation of hypocomplementemic and normocomplementemic urticarial vasculitis. J Am Acad Dermatol. 1998;38(6 Pt 1):899–905.
  32. Kulthanan K, Cheepsomsong M, Jiamton S. Urticarial vasculitis: etiologies and clinical course. Asian Pac J Allergy Immunol. 2009;27(2-3):95–102.
  33. Schwartz HR, McDuffie FC, Black LF, et al. Hypocomplementemic urticarial vasculitis: association with chronic obstructive pulmonary disease. Mayo Clin Proc. 1982;57(4):231–238.
  34. Jachiet M, Flageul B, Deroux A, et al. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol. 2015;67(2):527–534. doi: 10.1002/art.38956
  35. Tosoni C, Lodi-Rizzini F, Cinquini M, et al. A reassessment of diagnostic criteria and treatment of idiopathic urticarial vasculitis: a retrospective study of 47 patients. Clin Exp Dermatol. 2009;34(2):166–170. doi: 10.1111/j.1365-2230.2008.02891.x
  36. Davis MD, Brewer JD. Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome. Immunol Allergy Clin North Am. 2004;24(2):183–213. doi: 10.1016/j.iac.2004.01.007
  37. Grotz W, Baba HA, Becker JU, Baumgartel MW. Hypocomplementemic urticarial vasculitis syndrome: an interdisciplinary challenge. Dtsch Arztebl Int. 2009;106(46):756–763. doi: 10.3238/arztebl.2009.0756
  38. Sunderkotter C, Bonsmann G, Sindrilaru A, Luger T. Management of leukocytoclastic vasculitis. J Dermatolog Treat. 2005;16(4):193–206. doi: 10.1080/09546630500277971
  39. Berg RE, Kantor GR, Bergfeld WF. Urticarial vasculitis. Int J Dermatol. 1988;27(7):468–472. doi: 10.1111/j.1365-4362.1988.tb00921.x
  40. Chen YD, Krause K, Tu P, et al. Response of omalizumab in normocomplementemic urticarial vasculitis. J Allergy Clin Immunol Pract. 2020;8(6):2114–2117. doi: 10.1016/j.jaip.2020.02.024
  41. De Brito M, Huebner G, Murrell D, et al. Normocomplementaemic urticarial vasculitis: effective treatment with omalizumab. Clin Transl Allergy. 2018;8:37. doi: 10.1186/s13601-018-0222-y
  42. Rattananukrom T, Svetvilas P, Chanprapaph K. Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: a report of three cases and literature review. Asian Pac J Allergy Immunol. 2020;38(4):286–289. doi: 10.12932/AP-050918-0402

Supplementary files

Supplementary Files
Action
1. Fig. Stained skin biopsy section. The epidermis is of normal thickness, its layers are differentiated, weak loose keratosis. The walls of the vessels of the papillary and reticular layers of the dermis are thickened due to edema and swelling of endothelial cells. Around the vessels there is weak infiltration from histiocytes, lymphocytes, eosinophilic granulocytes. In places, single eosinophilic leukocytes penetrate the vascular wall. The number of eosinophils is from 7 to 12 in the field of view with a magnification of 400 times. The changes correspond to urticarial vasculitis.

Download (228KB)
Indexing metadata

Copyright © Pharmarus Print Media, 2021



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies